{
  "trial_id": "NCT03185988",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Signed informed consent.",
      "label": "met"
    },
    {
      "criterion": "Male and female patients aged from 18 to 75 years",
      "label": "met"
    },
    {
      "criterion": "Histologically confirmed Colorectal cancer,Esophagus squamous cell carcinoma, biliary tract cancer, and digestive system tumor beyond CRC and GC&GEJA with the following specifications:",
      "label": "unknown"
    },
    {
      "criterion": "genetic testing conformed KRAS/NRAS/BRAF all wild type for colorectal cancer",
      "label": "met"
    },
    {
      "criterion": "Detection of a carcinoma with HER2 3+ (IHC) or HER2 2+ (IHC) with amplification proven by fluorescence in situ hybridization(FISH), silver in situ hybridization\uff08SISH\uff09 or chromogenic in situ hybridization\uff08CISH\uff09 using gastric cancer criteria by an accredited local pathologist.",
      "label": "met"
    },
    {
      "criterion": "Relapse or metastatic diseases, at least one measurable lesion according to RECIST 1.1, anticipated survival \u2265 12 weeks.",
      "label": "unknown"
    },
    {
      "criterion": "ECOG Performance status 0-1.",
      "label": "met"
    },
    {
      "criterion": "Patients who failed at least first line systemic therapy.",
      "label": "unknown"
    },
    {
      "criterion": "Adequate organ function as determined by the following laboratory results: Absolute neutrophil count \u22651500 cells/mm3, Platelet count \u2265 90,000 cells/mm3, Hemoglobin \u22659.0 g/dL Total bilirubin \u2264 1.5 upper limit of normal (ULN). serum glutamate oxaloacetate transaminase(SGOT,AST), serum glutamate pyruvate transaminase(SGPT,ALT) < 2.5 ULN without liver metastases; < 5 ULN with liver metastases. serum creatinine < 1.5 ULN OR creatinine clearance \u2265 40 mL/ min.",
      "label": "unknown"
    },
    {
      "criterion": "If able to reproduce, patients must be willing to use highly effective methods of contraception during treatment and for 7 months after the end of treatment.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Known hypersensitivity against treatment regimen.",
      "label": "unknown"
    },
    {
      "criterion": "Baseline left ventricular ejection fraction(LVEF) < 50% (measured by echocardiography or MUGA).",
      "label": "unknown"
    },
    {
      "criterion": "Previous anti-her treatment.",
      "label": "met"
    },
    {
      "criterion": "Immune therapy, biological therapy or any participation in clinical trial in previous two weeks.",
      "label": "met"
    },
    {
      "criterion": "Surgery and not recovered in previous three weeks",
      "label": "unknown"
    },
    {
      "criterion": "Clinical evidence of brain metastases, or uncontrolled epilepsy.",
      "label": "met"
    },
    {
      "criterion": "Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.",
      "label": "met"
    },
    {
      "criterion": "Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.",
      "label": "unknown"
    }
  ],
  "notes": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a history of metastatic lesions and is using multivitamins and iron supplements.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT03185988",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}